Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States in 2017 for the reduction of
intraocular pressure in patients with open-angle
glaucoma
Glaucoma is a group of eye diseases that result in damage to the optic nerve (or retina) and cause vision loss. The most common type is open-angle (wide angle, chronic simple) glaucoma, in which the drainage angle for fluid within the eye rem ...
or
ocular hypertension.
It targets the
trabecular meshwork directly.
[
]
References
Ophthalmology drugs
Prostaglandins
Triols
{{pharma-stub